Targeted FLT3 inhibitors have been developed such as giltertinib, which was associated with significantly longer overall survival (OS) and higher complete remission (CR) rates compared to those with salvage chemotherapy in relapsed or refractory FLT3-ITD AML [10]. The gene discussed is FLT3; the disease is acute myeloid leukemia.